onclive· 2mo ago
save<![CDATA[HERIZON-GEA-01 Efficacy Results and Interpretation of Duration of Response]]>
May 14, 2026read original ↗
<![CDATA[HORIZON-GA01 shows zenidatamab regimens significantly improve survival in HER2-positive gastric cancer, while PD-L1 testing differences raise key questions for treatment choice.]]>
The original article is no longer reachable from this URL.
read full article on onclive ↗🔗 mentioned in this article
no entities indexed yet
comments(0)
5-min edit window · permanent after that